RSS-Feed abonnieren
DOI: 10.1055/s-0040-1717213
Safety of Metoclopramide in Traumatic Brain Injury Patients
Abstract
Introduction Traumatic brain injuries (TBIs) occur due to severe head assault to a hard object, with headache and vomiting being amongst the most common presenting symptoms. Metoclopramide is an old antiemetic agent that has been used widely for nausea and vomiting in TBI patients.
Aim A systematic review of the literature to investigate the safety of metoclopramide in treating TBI patients.
Methods A literature review was conducted in six databases, where we determined the pertinence of a study to the inclusion criteria by assessing the title, keywords, and abstracts. Five studies were found to be relevant. Data were extracted using multiple variables that were formulated incongruent with the study aim and then further analyzed.
Results The collective sample size was 93 patients with an average of age 38.5 years. As much as 51.6% were male and 48.6% were females. Most patients received 10 mg metoclopramide IV with a percentage of 77.4%, while only 22.5% received 20 mg IV metoclopramide. Seventy-one patients received metoclopramide alone and 22 received combination therapy. Headache was the most common reported side effect (46.2%), followed by anxiety and drowsiness with (39.7%) and (27.9%), respectively. Fatigue was reported in 24.7%, while dystonia was the least common and developed in only 5.3% of patients.
Conclusion Metoclopramide is a common medication used to treat TBI patients in the emergency department. However, the review demonstrated that the central nervous system (CNS) side effect is excepted. Treatments with lower CNS side effects may be better options.
Publikationsverlauf
Artikel online veröffentlicht:
29. September 2020
© 2020. Neurotrauma Society of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
-
Reference
- 1 Coronado VG, Xu L, Basavaraju SV. et al Centers for Disease Control and Prevention (CDC). Surveillance for traumatic brain injury-related deaths–United States, 1997-2007. MMWR Surveill Summ 2011; 60 (05) 1-32
- 2 Moezzi M, Delirrooyfard A, Motamed H, Mortazavi M. Antiemetic effects of metoclopramide with and without dexamethasone in children with minor head trauma: a single blind randomized clinical trial. Electron Physician 2018; 10: 7307-7313
- 3 Zamani M, Namdar B, Azizkhani R, Omid Ahmadi MED. Comparing the antiemetic effects of ondansetron and metoclopramide in patients with minor head trauma. J Emerg Med 2018; 3: 137-140
- 4 Friedman BW, Babbush K, Irizarry E, White D, Gallagher JE. An exploratory study of IV metoclopramide+diphenhydramine for acute post-traumatic headache. Am J Emerg Med 2018; 36 (02) 285-289
- 5 Maegele M, Lefering R, Sakowitz O. et al Inzidenz und Versorgung des mittelschweren bis schweren Schädel-Hirn-Traumas. Dtsch Arztebl 2019; 116: 167-173
- 6 Dickerson RN, Mitchell JN, Morgan LM. et al Disparate response to metoclopramide therapy for gastric feeding intolerance in trauma patients with and without traumatic brain injury. JPEN J Parenter Enteral Nutr 2009; 33 (06) 646-655
- 7 FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs.https://elbiruniblogspotcom.blogspot.com/2009/02/fda-requires-boxed-warning-and-risk.html. Accessed April 20, 2020
- 8 Nursal TZ, Erdogan B, Noyan T, Cekinmez M, Atalay B, Bilgin N. The effect of metoclopramide on gastric emptying in traumatic brain injury. J Clin Neurosci 2007; 14 (04) 344-348
- 9 van der Meer YG, Venhuizen WA, Heyland DK, van Zanten ARH. Should we stop prescribing metoclopramide as a prokinetic drug in critically ill patients?. Crit Care 2014; 18 (05) 502
- 10 Zamani M, Namdar B, Azizkhani R, Ahmadi O, Esmailian M. Comparing the antiemetic effects of ondansetron and metoclopramide in patients with minor head trauma. Emergency (Tehran) 2015; 3 (04) 137-140
- 11 Makkar JK, Gauli B, Jain K, Jain D, Batra YK. Comparison of erythromycin versus metoclopramide for gastric feeding intolerance in patients with traumatic brain injury: A randomized double-blind study. Saudi J Anaesth 2016; 10 (03) 308-313
- 12 Hale T, Kendall-Tackett K, Cong Z. Domperidone versus metoclopramide: self-reported side effects in a large sample of breastfeeding mothers who used these medications to increase milk production. Clinical Lactation 2018; 9: 10-17
- 13 Shakhatreh M, Jehangir A, Malik Z, Parkman HP. Metoclopramide for the treatment of diabetic gastroparesis. Expert Rev Gastroenterol Hepatol 2019; 13 (08) 711-721
- 14 Jolliet P, Nion S, Allain-Veyrac G. et al Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood-brain barrier. Pharmacol Res 2007; 56 (01) 11-17
- 15 Deehan S, Dobb GJ. Metoclopramide-induced raised intracranial pressure after head injury. J Neurosurg Anesthesiol 2002; 14 (02) 157-160
- 16 Altmayer T, O’Dell MW, Jones M, Martin V, Hawkins HH. Cisapride as a treatment for gastroparesis in traumatic brain injury. Arch Phys Med Rehabil 1996; 77 (10) 1093-1094